









Markets
/
Stocks
/
nasdaq-rcel
/

AVITA Medical Inc

RCEL

5.470USD

-0.070-1.26%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

145.58MMarket Cap

LossP/E TTM



AVITA Medical Inc

5.470

-0.070-1.26%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

119 / 506

Overall Ranking

223 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Hold

Current Rating

8.800

Target Price

+58.84%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

AVITA Medical, Inc. is a commercial-stage regenerative medicine company. The Company is a provider of regenerative medicine addressing unmet medical needs in burn injuries, full-thickness skin defects, and in skin repigmentation, such as vitiligo. Its RECELL platform a single use, stand-alone, battery operated, autologous cell harvesting device containing enzymatic and buffer solutions, sterile surgical instruments, and actuators. RECELL is used for the treatment of thermal burn wounds and full-thickness skin defects, and for repigmentation of stable depigmented vitiligo lesions. The platform technology of the RECELL System enables a thin split-thickness skin sample from the patient to be processed and prepared, producing an autologous cellular suspension called Spray-On Skin Cells. These Spray-On Skin Cells are prepared at the point of care in as little as 30 minutes, providing a new way to treat thermal burn wounds and full-thickness skin defects.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 86.66% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 64.25M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 131.93.

Overvalued

The company’s latest PE is -2.78, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 7.20M shares, decreasing 20.14% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 1.45M shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.99.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.24, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 18.42M, representing a year-over-year increase of 21.21%, while its net profit experienced a year-over-year increase of 35.56%.

Score

Industry at a Glance

Previous score

8.24

Change



Financials

5.25

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.27

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.67

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -2.82, which is 47.70% below the recent high of -4.16 and -235.25% above the recent low of -9.45.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 119/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 6.86, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for AVITA Medical Inc is 8.00, with a high of 14.00 and a low of 3.00.

Score

Industry at a Glance

Previous score

6.86

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Hold

Current Rating

8.800

Target Price

+60.88%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

AVITA Medical Inc

RCEL

CRISPR Therapeutics AG

CRSP

Exact Sciences Corp

EXAS

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 7.33, which is higher than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 7.07 and the support level at 4.07, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.33

Change

-0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.360

Neutral

RSI(14)

55.249

Neutral

STOCH(KDJ)(9,3,3)

50.618

Sell

ATR(14)

0.486

High Vlolatility

CCI(14)

58.027

Neutral

Williams %R

55.000

Sell

TRIX(12,20)

0.290

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

5.971

Sell

MA10

5.137

Buy

MA20

4.792

Buy

MA50

5.162

Buy

MA100

5.798

Sell

MA200

7.875

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 27.22%, representing a quarter-over-quarter decrease of 2.07%. The largest institutional shareholder is The Vanguard, holding a total of 1.45M shares, representing 5.45% of shares outstanding, with 0.88% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

1.72M

-1.19%

The Vanguard Group, Inc.

Star Investors

1.43M

+0.73%

Geode Capital Management, L.L.C.

619.71K

+3.70%

State Street Global Advisors (US)

526.95K

-1.50%

UBS Financial Services, Inc.

344.73K

+168.00%

Opaleye Management Inc.

440.00K

Northern Trust Investments, Inc.

252.16K

+18.02%

Wellington Management Company, LLP

82.21K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.64. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.